Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 3

  • 368 clinical trials
  • 123 recruiting
  • 134 conditions
  • 27 countries

Conditions in this area

134 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome28Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Rhinitis allergic16Dry age-related macular degeneration15Diabetic retinal oedema13Dry eye12Retinitis pigmentosa11Age-related macular degeneration10Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Rheumatoid arthritis6+110

Clinical trials in Eye disorders

368 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

368 clinical trials

Conjunctivitis allergic+1

Recruiting
Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

Diabetic retinal oedema

Recruiting
Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

Hepato-lenticular degeneration

Recruiting
Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Copper (64Cu) Chloride
  • Sponsor:Region Midtjylland

Neovascular age-related macular degeneration

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Medical University Of Graz

Cataract

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nepafenac
  • Sponsor:Medivis S.r.l.

Immunoglobulin G4 related disease

Recruiting
Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Still's disease+1

Recruiting
InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Herpes ophthalmic+1

Recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AGANIRSEN
  • Sponsor:University Of Cologne

Endocrine ophthalmopathy

Recruiting
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST THYROTROPIN RECEPTOR
  • Sponsor:Av7 Limited

Eye disorder

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:Asociacion Instituto De Investigacion Sanitaria Biobizkaia

Neovascular age-related macular degeneration

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Giant cell arteritis

Recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.